Global Cardiac Safety Service Market - Global Industry Size, Share, Trends, Competition, Opportunity, and Forecast, By Service Type (Thorough QT/QTc Study Services, ECG & Holter Monitoring Analysis, Blood Pressure & Telemetry Analysis, Cardiovascular Imaging (Echocardiography, MUGA), Real-Time Data Analytics & Reporting), By Service Delivery Model (In-house (Sponsor-run), Outsourced (CRO & Specialist Vendors)), By Clinical Trial Phase (Phase I, Phase II, Phase III, Phase IV / Post-marketing), By End User (Pharmaceutical Companies, Biotechnology Firms, Medical Device Manufacturers, Contract Research Organisations (CROs)), By Region, By Company 2021-2031F 2021-2031F

Key Insights	Details
Forecast Period	2026 - 2031
Market Size (2025)	USD 0.94 Billion
CAGR (2026-2031)	11.03%
Fastest Growing Segment	Real-time data analytics & reporting
Largest Market	North America
Market Size (2031)	USD 1.76 Billion

Market Overview

The Global Cardiac Safety Service Market is expected to grow from USD 0.94 Billion in 2025 to USD 1.76 Billion by 2031 at a 11.03% CAGR. The global cardiac safety service market encompasses specialized clinical research and drug development activities focused on comprehensively assessing and ensuring the cardiovascular safety profile of new pharmaceutical compounds, biologics, and medical devices. This market is primarily driven by expanding drug development pipelines and the increasing global burden of cardiovascular diseases. For example, according to the Pharmaceutical Research and Manufacturers of America, in 2025, 200 medicines were in development in the U.S. by American biopharmaceutical companies specifically targeting cardiovascular diseases. Additionally, stringent regulatory mandates from agencies such as the U.S. Food and Drug Administration and the European Medicines Agency, coupled with the rising complexity of clinical trials, necessitate robust cardiac safety evaluations. According to the Association of Clinical Research Organizations' 2026 State of the Industry Report, in 2025, its member companies conducted or participated in 7,634 studies involving 1.4 million patients and volunteers globally, underscoring the broad application of these services.

A significant challenge impeding market expansion is the substantial cost associated with comprehensive cardiac safety assessments, including advanced monitoring technologies and extensive data analysis. These expenditures can be considerable for drug developers.

Key Market Drivers

Global rise in cardiovascular disease drives cardiac safety demand
The rising global burden of cardiovascular diseases significantly drives the demand for cardiac safety services. As the prevalence and impact of heart-related conditions escalate worldwide, there is a heightened need for the development of new and effective cardiovascular therapies. This necessitates rigorous cardiac safety assessments for novel pharmaceutical compounds and medical devices during drug development to ensure patient well-being and regulatory compliance. According to the World Health Organization, in October 2026, ischaemic heart disease alone caused approximately 9.5 million deaths globally in 2023. This substantial health challenge compels pharmaceutical companies to accelerate research into cardiovascular treatments, inherently increasing the volume and complexity of cardiac safety evaluations required.

R&D investment and clinical trials propel cardiac safety services
Escalating pharmaceutical research and development and clinical trial activity also represent a major impetus for the cardiac safety service market. The continuous investment in discovering new drugs across various therapeutic areas leads to a larger pipeline of compounds that must undergo thorough cardiac safety profiling before market approval. According to PhRMA's Annual Membership Survey, in 2025, member companies invested more than $110 billion in research and development. This considerable expenditure in drug development, coupled with an increasing number of clinical trials, directly fuels the need for specialized cardiac safety services to monitor potential adverse cardiovascular effects. The overall pace of drug innovation underscores this demand, as illustrated by the fact that, according to Fierce Pharma, in January 2026, the FDA approved 46 novel drugs in 2025.

Download Free Sample Report

Key Market Challenges

Cost Burden of Comprehensive Cardiac Safety Assessments
The substantial cost associated with comprehensive cardiac safety assessments presents a significant challenge to the global cardiac safety service market. These expenditures, encompassing advanced monitoring technologies and extensive data analysis, place considerable financial strain on drug developers. Such high investment requirements can deter smaller biopharmaceutical companies or limit the scope of cardiac safety evaluations undertaken, particularly for compounds with perceived lower market potential.

R&D Spending Pressures and Cardiac Safety Services Expansion
This directly restricts the volume and depth of services procured within the market. According to the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA), annual estimated R&D expenditure for the pharmaceutical industry was projected to cross USD 200 billion by 2025, with clinical trials often accounting for approximately half of these total R&D costs. Within these large budgets, the specific and specialized nature of cardiac safety studies adds further financial pressure, impacting overall development timelines and resource allocation. Consequently, the elevated costs of these essential evaluations can lead to conservative spending by drug developers, thereby hampering the expansion of the cardiac safety service market.

Key Market Trends

AI/ML-Driven Advances in Cardiac Safety: Diagnostics and Efficiency
The integration of Artificial Intelligence and Machine Learning (AI/ML) is profoundly transforming the cardiac safety service market, particularly in enhancing diagnostic precision and accelerating data analysis. These advanced technologies are moving beyond theoretical applications to practical clinical utility, capable of interpreting vast datasets from cardiac assessments with improved accuracy and efficiency. A study published in The Lancet Digital Health on 2 November 2026 found that AI measurements of heart function from MRI scans were more accurate at predicting the risk of death than those by experienced clinicians in a cohort exceeding 27,000 patients. The AI tool also demonstrated significant efficiency, analyzing each patient scan in two to three seconds, compared to approximately 13 minutes for expert clinician assessment. This demonstrates AI/ML applications as indispensable for robust cardiac risk stratification and streamlining complex safety evaluations.

Remote/Wearable Monitoring Expansion and FDA Real-Time Trial Initiatives
The increasing adoption of remote and wearable cardiac monitoring technologies represents another pivotal trend reshaping the cardiac safety service market by facilitating continuous, real-time data collection outside traditional clinical settings. This shift supports more comprehensive assessments of cardiac function, crucial for detecting transient or asymptomatic cardiac events during drug development. The U.S. Food and Drug Administration (FDA) notably announced on 28 April 2026 the successful initiation of two proof-of-concept clinical trials as part of an initiative for real-time clinical trials, reporting endpoints and data signals to the agency instantaneously. Such regulatory endorsement underscores growing confidence in these technologies to enhance patient safety monitoring and improve clinical trial efficiency through continuous data streams, expanding monitoring reach and data depth.

Segmental Insights

Real-Time Cardiac Safety Analytics Driven by Regulatory Mandates and AI
The Global Cardiac Safety Service Market is witnessing rapid expansion in the Real-time data analytics & reporting segment due to evolving regulatory mandates and the increasing complexity of clinical trials. This growth is driven by the critical need for immediate insights into potential cardiac adverse events during drug development, particularly in early-phase studies and decentralized trials, where stricter International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) E14/S7B guidelines compel real-time proarrhythmia screening. Real-time analytics, often augmented by artificial intelligence (AI), enables faster detection of arrhythmias and other cardiac risks, facilitating prompt dose-escalation decisions and enhancing overall patient safety and data integrity. This capability helps sponsors optimize trial designs and supports regulatory submissions effectively.

Regional Insights

North America Leads Cardiac Safety Services Driven by Infrastructure, Regulation, and Disease Burden
North America leads the Global Cardiac Safety Service Market, primarily due to its sophisticated healthcare infrastructure and substantial investments in medical research and technology. The region benefits from a significant presence of pharmaceutical and biotechnology companies, which drives the demand for comprehensive cardiac safety assessments during drug development. Furthermore, stringent regulatory standards imposed by authorities such as the U.S. Food and Drug Administration (FDA) necessitate thorough cardiac evaluations in clinical trials, ensuring patient safety and fostering market growth. A high prevalence of cardiovascular diseases also contributes to the sustained demand for these specialized services across the region.

Recent Developments

• In November 2025, iRhythm Technologies published extensive real-world data and presented its findings at the AHA Scientific Sessions. This breakthrough research highlighted the effectiveness of its Zio® long-term continuous ECG monitoring system. The data demonstrated the superiority of Zio® monitoring over traditional short-term methods in detecting cardiac arrhythmias. This publication reinforced the clinical value of extended cardiac monitoring in identifying subtle or intermittent heart rhythm abnormalities. Such evidence directly supports advancements in the global cardiac safety service market by validating technologies that offer more comprehensive and reliable cardiac event detection for patient safety.
• In January 2025, Koninklijke Philips N.V. announced a collaboration with Myocardial Solutions Inc. to advance cardiac safety assessment. This partnership focused on developing AI-powered cardiac MRI systems. The objective of this breakthrough research was to improve the detection of cardiotoxicity, a common side effect of certain cancer drugs. By identifying these adverse cardiac effects earlier, the initiative aimed to prevent the onset of associated heart diseases, thereby enhancing patient safety in oncology treatments. This collaboration represents a significant step forward in integrating artificial intelligence with advanced imaging for comprehensive cardiac safety monitoring within the global cardiac safety service market.
• In June 2024, Clario received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its SpiroSphere® platform. This clearance was notable for the platform's integration with the wireless COR-12 ECG device. This advancement enabled the simultaneous collection of both respiratory and electrocardiogram data, offering a more comprehensive patient assessment. The new capability aimed to streamline data collection in clinical trials, particularly those requiring concurrent evaluation of cardiac and respiratory functions. This development is directly relevant to the global cardiac safety service market by providing an innovative tool for robust and efficient cardiac safety monitoring.
• In May 2024, VivaLNK Inc. introduced a new ambulatory cardiac solution designed to enhance remote patient monitoring capabilities. This new product launch integrated mobile cardiac telemetry (MCT) and Holter monitoring with advanced algorithms for detecting heart rhythm problems. The technology aimed to streamline the collection of continuous cardiac data and provide more efficient monitoring services. This advancement directly contributes to the global cardiac safety service market by offering improved tools for identifying cardiac arrhythmias and assessing drug safety in a decentralized clinical trial environment, ultimately supporting better patient care.

Key Market Players

• Natus Medical Incorporated
• Philips Healthcare
• Stryker
• Koninklijke Philips N.V.
• F. Hoffmann-La Roche Ltd.
• Johnson & Johnson
• Medtronic
• Boston Scientific
• Cardinal Health
• Abbott

By Service Type	By Service Delivery Model	By Clinical Trial Phase	By End User	By Region
Thorough QT/QTc Study Services ECG & Holter Monitoring Analysis Blood Pressure & Telemetry Analysis Cardiovascular Imaging (Echocardiography, MUGA) Real-Time Data Analytics & Reporting	In-house (Sponsor-run) Outsourced (CRO & Specialist Vendors)	Phase I Phase II Phase III Phase IV / Post-marketing	Pharmaceutical Companies Biotechnology Firms Medical Device Manufacturers Contract Research Organisations (CROs)	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Cardiac Safety Service Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Cardiac Safety Service Market, By Service Type:

• Thorough QT/QTc Study Services
• ECG & Holter Monitoring Analysis
• Blood Pressure & Telemetry Analysis
• Cardiovascular Imaging (Echocardiography, MUGA)
• Real-Time Data Analytics & Reporting

• Cardiac Safety Service Market, By Service Delivery Model:

• In-house (Sponsor-run)
• Outsourced (CRO & Specialist Vendors)

• Cardiac Safety Service Market, By Clinical Trial Phase:

• Phase I
• Phase II
• Phase III
• Phase IV / Post-marketing

• Cardiac Safety Service Market, By End User:

• Pharmaceutical Companies
• Biotechnology Firms
• Medical Device Manufacturers
• Contract Research Organisations (CROs)

• Cardiac Safety Service Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE